ClinicalTrials.gg
RecruitingNCT07002125Updated Aug 26, 2025

Whole Body Vibration Therapy in Individuals With Type 2 Diabetes

An interventional study of Whole Body Vibration and Aerobic Exercise in Type 2 Diabetes, Whole Body Vibration and Muscle Oxygenation, sponsored by Ankara Medipol University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Ankara Medipol University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey — 61 open to participants now, 71 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Turkey.

Planned enrollment
264th of 266
20 · median 100
Started
2025
with 25 others
No phase
150 of 342
33 open now
Primary completion
2025-12
later than 15 of 70 live
Registered
263rd of 342
by date

Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, this one is the 264th largest by planned enrollment of the 266 interventional ones that give a count, is one of 26 that started in 2025, is one of 150 with no phase, reaches primary completion later than 15 of the 70 other live ones, and was the 263rd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

61 of the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this interventional study is to investigate the effect of whole body vibration therapy on muscle oxygenation, vibration sensation, functional capacity and balance in individuals with Type 2 diabetes.

The main questions aimed to be answered are:

  • Does whole body vibration therapy affect peripheral muscle oxygenation?
  • Does whole body vibration therapy improve vibration sense, functional capacity and balance compared to aerobic exercise? Participants' muscle oxygenation, vibration sensation, functional capacity and balance parameters will be assessed. They will participate in a whole body vibration therapy or aerobic training program.
03

Conditions studied

  • Type 2 Diabetes
  • Whole Body Vibration
  • Muscle Oxygenation
  • Aerobic Exercise

Keywords

  • Aerobic exercise
  • diapason
  • balance
  • HbA1c
  • type 2 diabetes
  • whole body vibration
  • muscle oxygenation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteering to participate in the research
  • Being diagnosed with type 2 diabetes
  • 18 years of age or older
  • level to be 6.5-10%
  • Having a clinical history of diabetes between 2-10 years
  • Receiving oral hypoglycemic agent treatment
  • At least three HbA1c measurements within 12 to 24 months
  • variability score (HVS) \<50
  • Being able to walk independently
  • Mini mental test score ≥ 24
  • Vastus lateralis muscle adipose tissue thickness \<20mm
  • \<30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Previous or concurrent psychiatric, neurological, orthopedic or systemic illness
  • Use of insulin in treatment
  • Diabetic neuropathy
  • Foot ulcer
  • Participation in any exercise program in the last 6 months
  • History of major hypoglycemia in the last 12 months
  • Working or have worked in a job with high exposure to mechanical whole body vibrations
  • Conditions that may contraindicate whole body vibration (deep vein thrombosis, severe osteoporosis, active cancer, implanted medical devices, etc.)
  • Hearing, vision and perception problems that may affect research results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Aerobic Exercise

    The aerobic exercise group (AE) will participate in an ascending aerobic exercise program for 8 weeks, 3 sessions per week.

    Other: Aerobic Exercise

  • Experimental
    Whole Body Vibration

    The whole body vibration group (AE+TVV) will additionally participate in an 8-week incremental aerobic exercise program of 3 sessions per week.

    Other: Whole Body Vibration · Other: Aerobic Exercise

Interventions

  • OtherWhole Body Vibration

    Each exercise session will be performed with a frequency of 30 Hz and an amplitude of 2 mm. Participants are in a 110° squat position on the platform (the degree will be adjusted using a goniometer). Participants will exercise for 16 minutes from week one to week three, 20 minutes from week four to week six and 24 minutes from week seven to week eight, respectively (8 iterations and 1 minute of vibration with 1 minute interval between each iteration)

  • OtherAerobic Exercise

    From week one to week three, from week four to week six and from week seven to week eight, the participants will exercise for 30 minutes (5 minutes of running at 60-70% of heart rate and 5 minutes of active rest at 30-45% of maximum heart rate), 42 minutes (7 minutes of running at 60-70% of heart rate and 7 minutes of active rest at 30-45% of maximum heart rate) and 60 minutes (10 minutes of running at 60-70% of heart rate and 10 minutes of active rest at 30-45% of maximum heart rate). The exercise sessions consist of warm-up, main program and cool-down phases.

06

What researchers measure

Primary outcomes

  1. Muscle Oxygenation

    Vastus lateralis muscle oxygenation will be evaluated with Near-Infrared Spectroscopy at rest, during and after the 6-Minute Walk Test (6MWT)

    Time frame: 8 weeks

Secondary outcomes

  1. Vibration sense

    The sense of vibration will be assessed with a 128 Hz diapason. The lower end of the device will be brought into contact with the plantar surface of the first metatarsal bone, the medial malleolus, and the medial tuberosity of the tuberositas tibia in both lower extremities of the individual. The moment the diapozone touches the tested areas will be considered as the zero-second (0th second, start), and the test will be terminated when the individual perceives that the vibration disappears completely and the time will be recorded in seconds. Three trials will be performed on the areas in both lower extremities, and the average will be reported.

    Time frame: 8 weeks

  2. The Timed Up & Go Test

    It is a measurement that evaluates functional mobility, dynamic balance, fall risk and postural stability that can be applied for different purposes in different age and patient groups. The activities that make up the test evaluate the transition from sitting to standing position, walking, turning, and sitting again, which are necessary for functional mobility and dynamic balance. The TUG test measures the time it takes for an individual to get up from a standard chair with armrests and walk a distance of 3 meters, return from a designated or marked place, return to the chair, and sit back down.

    Time frame: 8 weeks

  3. The 6 minute walk test

    The individual is asked to walk on a certain track for 6 minutes. The test is performed in a closed area, on a flat surface of 30 m in length and under the supervision of the evaluator. After six minutes, the total distance walked is recorded in meters.

    Time frame: 8 weeks

  4. The 30-second Chair Stand Test

    In a chair with a sitting height of 43.2 cm and a back supported, the patient is asked to sit and stand as quickly as possible. The patient sits in the chair. They cross their hands on their chest. Before the test, 2 attempts are made. The number of sitting down times is noted by keeping a 30-second timer with a stopwatch. Less than 10 sit-ups in 30 seconds indicates lower extremity muscle weakness.

    Time frame: 8 weeks

  5. Balance

    Balance assessment will be performed with the Biodex Balance System (Biodex Medical Systems Inc., Shirley, NY, USA). The static balance test (eyes open-closed) test, which measures the angular movement of the center of gravity, will be used in the study.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Gazi University, Faculty of Health, Department of Physiotherapy and Rehabilitation
    Ankara, Çankaya, Turkey (Türkiye)
    Recruiting
    • Zeynep Hazar, Prof. Dr. · Contactzhazar@gazi.edu.tr · +90 312 216 26 21
    • Selcan Suicmez, Asst. Prof. · Principal investigator
    • Yusuf Kaan Kaya, MSc · Sub investigator
    • Faezeh Shamel, MSc · Sub investigator
    • Zeynep Hazar, Prof. Dr. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2025, 4 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 4 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2025
First posted
Jun 3, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07002125
Lead sponsor
Ankara Medipol University
Collaborators
Gazi University
Responsible party
Selcan Suicmez (Principal Investigator, Ankara Medipol University) — Principal investigator
First posted
Jun 3, 2025
Start date
Aug 1, 2025
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 26, 2025

Study contacts

Selcan Suicmez, Research Asst.
Contact
selcansuicmez@hotmail.com
+90 312 444 20 10 ext. 8823
Zeynep Hazar, Prof. Dr.
Contact
zhazar@gazi.edu.tr
+90 312 216 26 21

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion